Increased PSA after prostatectomy may not result in metastasis in some men's lifetime
the ONA take:
According to a new study published in the journal Clinical Cancer Research, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that some patients with prostate cancer whose prostate-specific antigen (PSA) levels become elevated after a radical prostatectomy may die as a result of a cause unrelated to prostate cancer before being diagnosed with cancer metastasis.
Therefore, active surveillance may be more beneficial than treating them for recurrence. For the study, the researchers analyzed data from various studies including patients with prostate cancer. Using this data, they created a simulation model to determine the number of patients with PSA recurrence who would die from unrelated causes in less time than it would take for PSA recurrence to cause metastasis in the absence of treatment.
They found that 9.1% and 15.6% of patients with prostate cancer whose PSA levels are elevated 5 years and 10 years after their initial treatment, respectively, may not experience metastatic disease before dying. Those patients are therefore overdetected for recurrence as the likelihood of recurrence before death is low. The simulation also found that 31.4% of men older than 70 with PSA recurrence within 10 years of initial diagnosis were overdetected.
Some patients whose PSA levels become elevated after prostatectomy may die of unrelated causes.
Some prostate cancer patients whose prostate-specific antigen (PSA) levels increase after a radical prostatectomy may die of causes unrelated to prostate cancer before they are diagnosed with a prostate cancer metastasis, and therefore treating them for recurrence may not be beneficial, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
"Previous studies have indicated that the interval from PSA recurrence to metastasis is quite long, with a median of more than eight years, even in the absence of any treatment for the recurrence," said Ruth Etzioni, PhD, full member of the Public Health Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, Washington. "Given that the majority of prostate cancer patients are older, we expect that many would die of other causes before reaching the point of metastasis.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
- PSA Screening Rates Level Off in United States
- CQGS Releases Standards for Surgical Care of Older Adults
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|